Rather than grimly assembling data about cancer deaths to predict outcomes in treatment, the founders of Cure51 had another idea.
Instead, the company assembles data about long term survivors of cancer, thus hoping to crack the code on what keeps people alive.
It’s now raised a €15 million Seed round led by Paris-based Sofinnova Partners.
Other investors in this round included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
Both had previously worked in five well-known oncology centers, such as the Gustave Roussy Institute in Paris and the Vall d’Hebronin Barcelona.
Leveraging resources such as virtual data rooms and shared labs makes it easier for biotech startups to grow.
“For this to work, the world would need to scale up the number of MRI scans it does by at least 100x.
Co-working for biotechShared lab spaces have been a game changer for biotech startups, Nature reported.
This reminded me of Startup Battlefield alum Parallel Health — its chief scientist officer Nathan Brown had mentioned shared labs in passing when we chatted at Disrupt.
“If you’re thinking about starting a company, try to visit a few just to see which one is the best.”Virtual data roomsVirtual data rooms are another important resource for biotech startups.
“Cooking with Lynja” star Lynn Yamada Davis, the TikTok creator known as “the internet’s grandma” and beloved for her quirky, educational cooking content, has died.
Her youngest son and co-creator of her social media channels, Tim Davis, announced his mother’s death in videos posted online on Friday.
“I’m super sad to inform you that unfortunately, Linda, my mom, has passed away,” Tim Davis said.
Tim Davis told the New York Times that his mother asked him to continue posting unreleased content after her death, which is why her account remained active this month.
In the most recent video, Tim Davis showed viewers photos of his mother throughout her life.
ImpriMed, a California-based precision medicine startup, builds AI-powered dog cancer treatment technology that helps veterinarians identify the most suitable drugs for individual canine and feline blood cancers.
The startup, which centers on improving treatment outcomes of dogs and cats with cancer first, now aims to expand its precision medicine technology for human oncology applications.
“Also, the proven know-how acquired from developing AI algorithms in veterinary oncology streamlines the building of new predictive models in human oncology.
For human precision oncology, its AI software for multiple myeloma, a rare blood cancer, is in the process of approval, aiming to commercialize in 2025, Lim told TechCrunch.
ImpriMed’s unique strength is “the ability to develop and incorporate AI models into the personalized medicine service workflow,” according to Lim.
At Pragma Bio, they believe that the human body is teeming with miraculous microbes that can help us avoid diseases and even extend our lifespan. With their new funding, they…
